Evidence for participation of B1 and B2 kinin receptors in formalin‐induced nociceptive response in the mouse
Authors:
Open Access
- 1 September 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 110 (1) , 193-198
Abstract
This study was designed to investigate the role of bradykinin (BK), as well as the subtype of BK receptors involved, in formalin‐induced hindpaw pain in the mouse by use of selective B1 and B2 receptor antagonists. In addition, we have analysed whether or not BK may be involved in formalin‐induced hindpaw oedema in the mouse. The pretreatment of animals with captopril (2 and 5 mg kg−1, s.c.) significantly increase the first and the second phases of formalin‐induced pain. Co‐injection of the selective B1 receptor antagonist des‐Arg9[Leu8]‐BK (0.2–0.4 nmol/paw), together with formalin, caused graded and similar inhibitions of both phases of formalin‐induced pain. Similar results were obtained with the B2 antagonists NPC 349 (d‐Arg[Hyp3,Thi5,8‐d‐Phe7]‐BK) and NPC 567 (d‐Arg[Hyp3, d‐Phe7]‐BK) (0.2 and 0.6 nmol/paw). Higher concentrations of these antagonists (1 nmol/paw) failed to antagonize formalin‐induced pain. The new potent and selective B2 receptor antagonists, Hoe 140 (d‐Arg[Hyp3,Thi5,d‐Tic7,Oic8]‐BK), NPC 17731 (d‐Arg[Hyp3, trans‐4‐propoxy‐d‐proline (transpropyl)7, Oic8]‐BK), and NPC 17761 (d‐Arg[Hyp3, trans‐4‐propoxy‐d‐proline (trans thiophenyl)7, Oic8]‐BK) (0.02 to 1.0 nmol/paw), also caused significant inhibitions of both phases of formalin‐induced pain. When Hoe 140 was injected subcutaneously 30 min before formalin injection (9.9 and 99 nmol kg−1), it significantly attenuated both phases of formalin‐induced pain. The putative non‐peptide BK antagonist, MV 8612 (1.6 to 9.6 nmol/paw), but not MV 8608 (5.5 to 33 nmol/paw), caused a graded inhibition of both phases of formalin‐induced pain, being, however, more active against the first phase. The pretreatment of animals with morphine (2.6 to 13μmol kg−1, s.c.) caused dose‐dependent and equipotent inhibitions of both phases of formalin‐induced pain. In contrast, indomethacin (2.7 to 27 μmol kg−1) antagonized only the second phase of formalin‐induced pain. The B2 receptor antagonists, Hoe 140, NPC 17731, NPC 17761, NPC 349 and NPC 567, all caused a significant inhibition of formalin‐induced hindpaw oedema. A similar inhibition was also observed with indomethacin but not with captopril or morphine. Our results provide strong evidence for the important role of endogenous BK, acting through both B1 and B2 receptors, in the genesis of both phases of formalin‐induced persistent pain in the mouse. In addition, the current results also demonstrate that the inflammatory oedema associated with the later phase of formalin‐induced pain seems to be mediated by endogenous BK, via activation of B2 receptors.Keywords
This publication has 38 references indexed in Scilit:
- Biochemical and Molecular Pharmacology of Kinin ReceptorsAnnual Review of Pharmacology and Toxicology, 1992
- Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptidesJournal of Medicinal Chemistry, 1991
- Bradykinin AntagonistsAnnual Review of Pharmacology and Toxicology, 1991
- Design and conformational analysis of several highly potent bradykinin receptor antagonistsJournal of Medicinal Chemistry, 1991
- Methodological refinements to the mouse paw formalin testJournal of Pharmacological Methods, 1988
- Kinin Formation: Mechanisms and Role in Inflammatory DisordersAnnual Review of Immunology, 1988
- Interaction of Bradykinin with Substance P on Vascular Permeability and Pain ResponseThe Japanese Journal of Pharmacology, 1986
- Pharmacology of kinins: Their relevance to tissue injury and inflammationGeneral Pharmacology: The Vascular System, 1983
- Morphine analgesia in the tail-flick and Formalin pain tests is mediated by different neural systemsExperimental Neurology, 1982
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977